GLOW Peptide Blend: What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

GLOW is a product name, not a molecule: a mixture of three peptides (GHK-Cu, BPC-157 and TB-500) sold in one vial for injection under the skin and promoted for younger-looking skin, hair growth and faster recovery from injury. The strongest evidence near it belongs to one ingredient used a different way: GHK-Cu applied to the skin as a cream or serum has been tested in people in small trials, with mixed results. No published study has tested the three together in people, in animals or in cells; the one experiment that compared two of them together with each alone, in rats, found no added benefit; and no dose of the blend has been tested in people.

This review covers what a vial sold as GLOW is said to hold, where such a blend stands with the FDA, and what is and isn’t known about the mixture; each ingredient has its own review in our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Not FDA-approved, and outside the FDA’s and HHS’s compounding policies: HHS’s draft policy applies to single-ingredient products only.
Evidence in people
None for the blend. No published study has given the three together to people or to animals.
The claim you’ve heard
Synergy between the three: not tested. The one rat study of two of them found no added benefit.
Doses tested in people
None for the blend, and no under-the-skin dose of any of its ingredients given alone.
Sport
BPC-157 and TB-500 are named on WADA’s Prohibited List, prohibited at all times. GHK-Cu is not named.

What GLOW is

No pharmacopoeia, regulator or published paper defines “GLOW”, and searches of PubMed, Europe PMC and ClinicalTrials.gov found no record that uses the name for a peptide product. It is a market label for three peptides mixed in one vial, usually sold as a freeze-dried powder.

Ingredient What it is
GHK-Cu Three amino acids (glycine, histidine and lysine) bound to one copper ion.
BPC-157 A synthetic peptide 15 amino acids long.
TB-500 As the FDA and HHS define it, a seven-amino-acid fragment of thymosin beta-4 with an acetyl group added. Not thymosin beta-4 itself, a 43-amino-acid protein.

The formula is not fixed. What a vial holds is known only from what sellers and other pages state. The amounts stated most often are 50 mg of GHK-Cu with 10 mg each of BPC-157 and TB-500. A clinic’s blog states 27 mg of GHK-Cu, 10 mg of TB-500 and 5 mg of BPC-157; a consumer’s report to the FDA gives 100 mg, 10 mg and 10 mg; and two sellers’ help pages title the product a “50 mg Vial” without listing its contents.

The name doesn’t settle which thymosin is in the vial. Some pages treat TB-500 and thymosin beta-4 as one thing, and a seller’s press release gives “TB-500” the molecular weight of the full-length protein.

Two related blends are not reviewed here: KLOW (the same three plus a fourth peptide, KPV) and “Wolverine” (BPC-157 with TB-500, no GHK-Cu).

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: an injection that mixes these peptides is not an FDA-approved medicine, and it falls outside the two federal policies in which HHS and the FDA say they do not intend to act against certain compounding. HHS, the federal department the FDA belongs to, limits its draft policy to products with a single active ingredient, and the FDA’s guidance says a drug compounded from an ingredient outside the federal compounding law’s three conditions “may violate the FD&C Act” (the federal Food, Drug, and Cosmetic Act).

As of November 19, 2026, compounded injections that combine two or more of these peptides are not FDA-approved, and they fall outside HHS’s draft interim policy of October 30, 2026, which applies only when “the compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A.” They are outside the FDA’s own Category 1 policy as well. The FDA’s guidance says a drug compounded from a substance outside section 503A’s three conditions “is not eligible for the exemptions in section 503A and may violate the FD&C Act.”

Compounding here means a licensed pharmacist or physician making a medicine for one identified patient on a prescription; section 503A is the part of federal law that sets its conditions. The three conditions concern the ingredient: an official monograph, use in an FDA-approved drug, or a place on the FDA’s list. None of GLOW’s ingredients meets any of them. (Category 1 is the FDA’s list of ingredients under evaluation; Appendix A is HHS’s list of six peptides.)

Why HHS’s draft policy leaves blends out. HHS’s policy, a draft interim policy announced on October 30, 2026, is the only federal document we read that addresses blends of these peptides. Its conditions must all be present, and a single active ingredient is one of them. HHS’s reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance, which is essential for meaningful safety surveillance and signal detection, if compounded peptide products include a single API.”

Each ingredient on its own. BPC-157 and TB-500 are each named in HHS’s policy only as a single-ingredient acetate salt, in the dosage forms it lists, for a patient-specific prescription; that does not carry over to a blend. GHK-Cu by injection is in no FDA category and is not on HHS’s list.

Sport. BPC-157 (class S0) and TB-500 (class S2.3) are named on WADA’s 2026 and 2027 Prohibited Lists, in classes prohibited at all times. GHK-Cu is not named on either List, though WADA’s note for 2027 says an unnamed peptide “may still be prohibited”.

Claims you’ll see, and why sources disagree

Pages about GLOW run ahead of the research in three ways.

  • One ingredient’s evidence, from one way of using it, is presented as the blend’s. No page we read cites a study of the combination. The evidence borrowed belongs to other things: GHK-Cu applied to the skin, BPC-157 given by enema or into a joint, and thymosin beta-4, a different molecule from TB-500.
  • Acting on different stages of repair is read as adding up. The authors of a 2026 review, clinicians who themselves inject BPC-157 with TB-500, wrote that “mechanistic complementarity should not be considered as evidence of clinical synergy or pharmacological compatibility”.
  • A citation doesn’t hold what is claimed. A telehealth marketplace’s article says “A 2025 IV safety pilot confirmed tolerability of the blend up to 20 mg in two healthy adults with no adverse effects”. Its reference is a clinic’s blog that mentions no pilot, and we found no such study of the blend. The one published study that fits gave BPC-157 alone (that it is the study meant is our inference).

“Not tested” is not the same as “doesn’t work”. It means nobody knows, and it cuts both ways: the blend has not been shown to help people, and it has not been shown to be safe for them.

Claim Evidence for the blend Its ingredients, alone or in pairs: level, and how given
The three work in synergy Not tested in any species Animal studies: the one test of a pair against its parts, in rats, found no added benefit
Younger-looking skin Not tested Tested in people, GHK-Cu on the skin only: one maker-funded trial positive, one small trial negative on objective measures
Hair regrowth Not tested Tested in people: one 18-person trial of a GHK-Cu serum on eyebrows; no trial of GHK-Cu alone for scalp hair loss
Faster recovery, less inflammation Not tested Animal studies and lab studies; reported in people in one uncontrolled knee survey of BPC-157
“Safe”, “well tolerated” Not established; no safety study of the blend exists No human safety data for injected GHK-Cu or for TB-500. BPC-157: about 83 people by other routes, and five under the skin, with thymosin beta-4, in one unblinded pilot

What the evidence consists of

Only evidence for the blend itself is evidence for GLOW. Evidence for two of the three given together, or for one ingredient given one way, is not.

Tested in people

The three together: none. We found no trial, case series or published case report of the three given together, and no registered trial (PubMed, Europe PMC and ClinicalTrials.gov, searched November 19, 2026; registries outside the United States were not searched).

BPC-157 with thymosin beta-4, in one small pilot (Majumdar and colleagues, 2026). Ten adults with a spinal cord injury had rehabilitation; five also had BPC-157 and thymosin beta-4 (the parent protein by the paper’s description, not TB-500) under the skin weekly for 26 weeks, as separate injections. The five scored higher on leg movement at six months, but the study was not randomized or blinded, had no placebo or single-peptide group, and its authors call the results “hypothesis-generating only”. It reported no serious adverse events; its counts of milder ones disagree. Its stated registration could not be found in the registry, and its funding line reads “To be declared”.

Reported in people: pairs, not the blend

Only the first report below gave two of GLOW’s ingredients; the other two gave one ingredient with what they name as thymosin beta-4, the parent protein, not TB-500. None had a comparison group, and none is a test of the blend.

Report People What was given What happened Limits
Froum and colleagues, 2026 3 adults with nerve injury after dental surgery BPC-157, TB-500 and three other agents, under the lining of the mouth Near-complete return of sensation; no adverse events reported Five agents at once; such injuries can recover on their own
Lee and Padgett, 2021 16 adults with knee pain; 4 had both peptides BPC-157 into the knee, with thymosin beta-4 in 4 Of the 4, “75% showed significant improvement, but 25% had no relief of their knee pain” Ratings by recall 6 to 12 months later
Kapoor and Shome, 2018 “1000 patients”, open-label Copper tripeptide-1 (GHK-Cu), thymosin beta-4 and four growth factors, into the scalp “Significant reduction in hair fall was seen in 83% of the patients on hair pull test” Six actives at once; by the developers, who hold the patent

Each ingredient on its own, in people

None of the ingredients’ own records matches how the blend is used: none has been studied alone in people by injection under the skin. Each record is set out in its own review: GHK-Cu, BPC-157 and TB-500.

Animal studies

The three together: none found, and no animal or cell study of GHK-Cu with either of the other two.

BPC-157 with “TB-500”: one rat study (Biçer and colleagues, 2026). Thirty-two rats had an Achilles tendon cut and repaired and were put in four groups of eight: control, BPC-157, “TB-500”, or both, the peptides injected into the abdomen daily for 30 days. The median load a tendon bore before failing (four rats per group) was 26.91 N in the control group, 37.16 N with BPC-157, 37.41 N with TB-500 and 34.54 N with both; only TB-500 differed significantly from control. On one tissue score, TB-500 and the combination each differed significantly from control (on a second, the combination did not), and “No statistically significant differences were observed among treatment groups.” The authors, who report no funding and call the study “exploratory”, concluded: “Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.” Its “TB-500” is described only as “a synthetic peptide derived from Tβ4”, so it is unconfirmed that it was the acetylated fragment.

Lab studies and how it is thought to work

For the blend, nothing has been shown, and the claim that the three act on different stages of repair and so add up is theory. Of BPC-157 the FDA says “the molecular targets for BPC-157 have not been identified”.

Three peptides and copper in one solution (inference from lab chemistry). We found no paper that reports the stability of any two of these three in one solution. The chemistry predicts that copper stays mostly with GHK, which binds it tightly; nobody has measured that, and whether the other two peptides attach to the copper complex is untested.

Dosing: what has been tested, what is used, and what the reasoning supports

This section reports and reasons; it recommends nothing. No study has given any amount of the blend to people or compared one amount with another, so no dose can be called optimal.

Doses tested in people

For the blend, none: no amount of the three mixed together has been given in any published or registered human study. Two of the ingredients have been given together only in the three dental cases: BPC-157 1 mg with TB-500 10 mg, alongside three other agents, under the lining of the mouth, weekly for 4 weeks. BPC-157 has been given with thymosin beta-4 into the knee in four patients (BPC-157 2 to 4 mg in one or two injections, on the FDA’s reading; thymosin beta-4 dose not stated) and under the skin in the pilot’s five (BPC-157 0.8 mg and thymosin beta-4 1.65 mg weekly for 26 weeks, in a study not designed to find a dose).

Singly, GHK-Cu has been tested in people only on the skin; BPC-157 by enema, into a knee joint, into the bladder wall and, in two people, by vein; and TB-500, the fragment, only in the three dental cases. No published human study has given the blend, or any of the three on its own, under the skin, which is how pages say the blend is used.

Doses in common use

These are amounts in circulation: practice that no trial set, reported so that you can see where each figure comes from. No human study used any of them: none of the three has been studied alone under the skin, and the pilot gave BPC-157 weekly, not daily.

  • One injection under the skin a day, sized by its GHK-Cu. Two research-peptide sellers’ help pages (near-identical, so one origin) state a “Typical daily dose: 2,330 mcg (2.33 mg) once daily for 4 weeks”, “delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157 per injection”. A newsletter post describes 1 mg or 2 mg of GHK-Cu a day, with the other two in whatever amount the vial’s proportions bring: “The other peptides come along for the ride”. No trial set these amounts.
  • A separate range for each ingredient. A telehealth marketplace’s article gives “GHK-Cu at 1 to 2 mg per day, BPC-157 at 250 to 500 mcg per day, and TB-500 at 2 mg twice weekly, administered subcutaneously”. A pharmacist-hosted podcast gives BPC-157 “between 200 and 500 micrograms a day”, TB-500 “about 2 to 5 milligrams per week” and GHK-Cu “in the 100 to 300 microgram per day range”. No trial set any of these ranges.
  • Cycles and breaks. From 4 weeks on and 2 to 4 weeks off (the sellers’ pages) to 4 to 12 weeks on and 1 to 2 months off (the podcast). No study has tested any cycle.

What the pharmacology supports, and what it doesn’t

  • Amount. Not measured: no study in people has compared amounts of the blend, or of any ingredient under the skin, so nothing links an amount to an effect. Inferred: in one vial the three amounts move together, so one cannot be changed without the others.
  • Frequency. Measured in animals: BPC-157’s half-life was under 30 minutes in rats and dogs; TB-500 given under the skin of horses could no longer be measured in their blood after 6 to 10 hours; GHK given by vein to rats “was rapidly degraded”. Not measured: blood levels of any of the three in people after an injection. Inferred: no one schedule can be derived for three molecules, and the once-daily pattern follows from the vial, not from these data. How often would be right, if any schedule is, and for how long, are unknown.
  • Copper. Computed: a milligram of one-to-one GHK-Cu carries about 0.16 mg of copper; neither the form nor the true content of marketed vials is established. Inferred: injected copper bypasses the gut, which regulates how much swallowed copper is absorbed; a 2026 review says dietary limits “cannot be converted directly into parenteral limits” (limits for injection).
  • Monitoring. Inferred: a prescriber would sensibly watch injection-site and allergic reactions, copper status and liver enzymes, clotting tests in anyone taking a blood thinner, and cancer history. No marker has been validated for any of the three.

What nobody knows: whether any amount of the blend does anything in a person, what amount would be harmful, and whether the three interact in the vial or in the body.

What common protocols get wrong

  • Figures trace to no study. One of the sellers’ pages says its regimen “aligns with common research protocols for BPC-157 and similar repair peptides” and names none. The marketplace article’s only citation for its figures is an influencer’s blog which, as read on November 19, 2026, does not contain them.
  • The figures contradict each other, and the vial. The podcast’s GHK-Cu range is about a tenth of the others’. It also calls for more BPC-157 than GHK-Cu a day, which the vial the same page describes cannot deliver.
  • A mechanism is supplied for the breaks. An influencer’s blog says to take “at least 15 days off between cycles to prevent receptor desensitization”. For BPC-157 no receptor has been identified.

A dose is a prescriber’s decision for one patient. For this blend, no published study in people exists to base it on.

Safety, and who should be most cautious

No study has measured the safety of the blend.

Reports to the FDA. We found one adverse-event report that names the blend: a consumer’s, received in May 2026, about a 31-year-old man. It lists the blend as taken alongside two medicines the reporter marked as suspect, and its reaction terms include “Malignant lymphoid neoplasm” (a cancer of the lymph system). It does not show that the blend, or anything else on the report, caused the cancer: the FDA’s database says “a causal relationship cannot be established between product and reactions listed in a report”. Five other reports name BPC-157, GHK-Cu or a thymosin product, most alongside other products; such reports are not a count of harms and cannot separate one product from another. The FDA’s review of BPC-157 describes darkening of the skin and gums in a user of a “research purposes only” BPC-157 and TB-500 product, which returned when the product was restarted; the FDA calls it unclear whether BPC-157 was the cause.

What the FDA has said. Nothing about combining these peptides. Of each of the three it says compounded drugs may “pose risk for immunogenicity” (an unwanted immune reaction): injectable ones for GHK-Cu, and “for certain routes of administration” for BPC-157 and TB-500. Of TB-500 it adds that it “has not identified any human exposure data”, and of BPC-157 that “the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”

Theory, labelled as theory. People with cancer, now or in the past, have the most reason for caution, on theory alone: each of the three has been reported to promote new blood-vessel growth in animal or cell work (for TB-500, in tests of a seven-amino-acid stretch of thymosin beta-4, not of a TB-500 product), and tumours need new vessels. Whether the concern is larger for the combination is unknown. People with Wilson disease, who cannot clear copper normally, are a second group: the blend carries copper, and no GHK-Cu study included them.

Situation What is known Basis
Pregnancy and breastfeeding No human data for any of the three No published studies in people
Cancer, now or in the past No human data; a theoretical concern for each of the three Animal studies and lab studies of blood-vessel growth; theory
Other medicines, and the three with each other No interaction study of any kind No published studies
Tested athletes BPC-157 and TB-500 are prohibited at all times WADA’s 2026 and 2027 Lists

Product quality

No analysis of a mixed vial. We found no published analysis of the identity, content, purity, copper content or sterility of a product containing these three peptides. A mixed vial is also harder to check (inference): it has three identities and three amounts to confirm, plus the copper, and a peptide can pass a test after its copper has left it.

What testing of single peptides found. The largest dataset on peptides sold online (Mendias and Awan, 2026, a preprint, not peer-reviewed) analysed test reports that consumers and vendors submitted for fourteen compounds, GLOW’s three ingredients among them, each sold singly. Across the fourteen, “41.6% to 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples” (endotoxin: a contaminant from bacteria). For TB-500, “one in ten TB-500 samples did not contain the stated compound”. GHK-Cu “had the highest median purity at 99.90%”, but the paper measured no copper. The authors say the dataset “is not a random or representative sample” and call the failure rates “a lower bound”.

FDA records. We found no FDA recall or warning letter that names GLOW (the search was not exhaustive). Three recalls, in 2025 and 2026, name pharmacy-compounded vials of BPC-157 with thymosin beta-4 or with KPV; each was part of a recall of dozens of that pharmacy’s products, for “Lack of Assurance of Sterility” or “Lack of Processing Controls”.

“Research use only”. In a warning letter of August 24, 2026 to an online seller of other peptides, the FDA wrote: “Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”

What we make of it

This section is our reading of the evidence. It is a judgment, not a finding.

On the evidence, GLOW is unproven and experimental twice over: none of its three ingredients has been tested on its own in people by injection under the skin, and we found no study of the mixture in people, animals or cells.

That does not mean it does nothing. Each ingredient has animal or lab findings behind the claims made for it, GHK-Cu on the skin has some weak support in people, and an absence of studies is not evidence of no effect.

Where the claims outrun the evidence is the blend itself. The case for combining rests on synergy, and the only test of a pair against its parts, in rats, found none. The single vial also has costs: the three amounts are locked together, nothing that happens can be traced to one ingredient, and nobody has reported how the three behave in one solution with copper.

Three things would have to be shown first: basic safety and blood-level data in people for each ingredient by injection; that the mixture is stable; and, in a study that compares them, that the blend does more than its ingredients given singly.

For whom a blend like this might ever be considered, after what, with what monitoring and when to stop are clinical judgments, and they are our Medical Director’s to state.

Peptide care at Rock Creek Wellness

Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

  • A study of the three together, in people or in animals. ClinicalTrials.gov listed no study combining any two of these peptides on November 19, 2026.
  • Stability data for the three in one solution, and an independent analysis of mixed vials.
  • Regulatory decisions: the FDA’s advisory committee on GHK-Cu, planned before the end of February 2027, and rulemaking: HHS’s draft policy is written to last “Until a peptide bulk drug substance is addressed in a final rule”.

Common questions

Does GLOW work?

Nobody knows, because no published study has tested the blend in people, in animals or in cells. The evidence quoted for it belongs to its ingredients used singly and in other ways, such as GHK-Cu applied to the skin.

Is GLOW safe?

That is unknown. No study has measured the safety of the blend, and there are no human safety data for any of its ingredients given alone under the skin.

Is GLOW FDA-approved?

No. None of its three ingredients is an FDA-approved drug, and a compounded blend of them falls outside HHS’s draft policy on peptide compounding, which applies to single-ingredient products only.

Can a doctor prescribe GLOW?

The FDA and HHS documents we read give no yes or no about prescribers: their conditions attach to the compounding and to the product, not to the writing of a prescription. GLOW is not FDA-approved, so any prescription would be for a compounded medicine, of a kind the FDA’s guidance says “may violate the FD&C Act”.

How much GLOW do people take, and how often?

No amount or schedule of the blend has been tested in people, so there is no evidence-based answer. Sellers’ pages and a newsletter describe one injection under the skin a day carrying about 1 to 2 mg of GHK-Cu; that is practice no trial set, and a podcast gives a GHK-Cu figure about a tenth of that.

Sources

Show all 31 sourcesHide sources
  1. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
  2. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
  3. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
  5. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027). US Food and Drug Administration, 2026.
  6. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. US Food and Drug Administration, 2026.
  7. FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. US Food and Drug Administration, 2026.
  8. WADA 2026 Prohibited List; WADA 2027 Prohibited List; Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.
  9. ClinicalTrials.gov. US National Library of Medicine, searched 2026.
  10. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
  11. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health, 2026.
  12. Regenerative peptides for inferior alveolar nerve injury: a narrative review. Frontiers in Dental Medicine, 2026.
  13. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021.
  14. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025.
  15. Adjunctive Weekly Subcutaneous Thymosin β4 and BPC-157 With Intensive Rehabilitation in Subacute AIS-B Thoracic Spinal Cord Injury: A 6-Month Open-Label Controlled Pilot Study. American Journal of Medical and Clinical Research & Reviews (not indexed in PubMed), 2026.
  16. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth – safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy, 2018.
  17. QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. Plastic and Reconstructive Surgery Global Open, 2020.
  18. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science, 2016.
  19. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006.
  20. The Efficacy of 2% Copper Peptide (GHK-Cu) Serum for Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled, Split-Face Comparative Study. Procedia of Multidisciplinary Research, 2026.
  21. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. Journal of Biological Inorganic Chemistry, 2012.
  22. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 2026.
  23. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022.
  24. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A, 2012.
  25. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. Journal of Chromatography B, 1997.
  26. Copper: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements, 2022.
  27. openFDA drug adverse event data (FAERS). US Food and Drug Administration, 2026.
  28. About the drug adverse event endpoint. US Food and Drug Administration, 2026.
  29. openFDA drug enforcement (recall) data. US Food and Drug Administration, 2026.
  30. Warning Letter: Peptide Partners LLC, 735063, 08/24/2026. US Food and Drug Administration, 2026.
  31. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org (not peer-reviewed), 2026.